Personalis, Inc. (PSNL) key performance indicators and operating metrics (13 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Clinical Tests Delivered | 7.82K | FY2026-Q1 |
| Other Revenue | 424K | FY2026-Q1 |
| Pharma Testing Services Revenue | 10.72M | FY2026-Q1 |
| Population Sequencing Revenue | 2.5M | FY2026-Q1 |
| Clinical Diagnostic Revenue | 1.43M | FY2026-Q1 |
| Clinical Test Revenue from NextDX and NextPersonal | 1.4M | FY2026-Q1 |
| Clinical Tests Sequential Growth Rate | 26.00 percent | FY2026-Q1 |
| Clinical Tests Year-Over-Year Growth Rate | 258.00 percent | FY2026-Q1 |
| Pharma Testing Services and All Other Customers Revenue | 10.9M | FY2025-Q4 |
| Gross Margin | 13.20 percent | FY2025-Q3 |
| Cash Usage from Operations and Capital Equipment Additions | 23.4M | FY2025-Q3 |
| Enterprise Sales Revenue from Natera | 2.32M | FY2025-Q2 |
| Revenue from Population Sequencing for the Veterans Affairs Million Veteran Program | 200K | FY2024-Q4 |
Back to PSNL overview · PSNL earnings · PSNL holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.